




#IAMRESILIENT2021
 Join the "31 Days of Resilience."
 If we are individually resilient, we are a resilient myeloma community.
 This March, bolster your resilience with a new self-care activity each day of the month.
 Share on social media and encourage others to join!



START TODAY



March 2021

MARCH IS MYELOMA ACTION MONTH!

IMF Support Group Monthly Newsletter – Connecting Communities!

Thank you for your actions during Myeloma Action Month to help increase awareness of multiple myeloma! We hope the below links and resources are helpful to you in preparation for your April virtual meetings!

Ask Dr. Durie

- March 10: What is Pepaxto (Melphalan Flufenamide), a medicine recently approved by the FDA. [Watch here](#)
- March 17: COVID-19 FAQ #26: Should myeloma patients get vaccinated against COVID-19? [Watch here](#)
- March 24: What is ide-cel and how can it benefit myeloma patients. [Watch here](#)

IMF Blogs

- March 4: Exciting progress in myeloma: FDA approval of Melphalan Flufenamide and important research results published. [Read here](#)
- March 11: New relapse guidelines highlight key role of International Myeloma Working Group experts. [Read here](#)
- March 18: Myeloma research continues and COVID-19 understanding evolves. [Read here](#)
- March 25: Virtual vacation: A visit to a galaxy far, far away and an encounter with ancient woolly mammoth DNA. [Read here](#)

Other Myeloma Updates, Publications and Information

- March 3: This International Women’s Day the International Myeloma Foundation proudly recognizes our President, Founder, and CEO Susie Durie. [Read here](#)
- March 8: International Myeloma Foundation launches “M-Power Charlotte” to improve outcomes in multiple myeloma, a cancer that disproportionately affects African Americans. [Learn more here](#)
- March 21: Editor’s Corner: Post-Pandemia Mania. [Read here](#)
- March 24: Many options, many updates to NCCN guidelines in Multiple Myeloma. [Read here](#)
- March 26: International Myeloma Foundation says FDA approval of Bristol Myers Squibb’s and Bluebird Bio’s CAR T-Cell Immunotherapy Treatment for multiple myeloma is welcome news for patients. [Learn more here](#)
- March 30: European Commission approves conditional marketing authorization for NEXPOVIO. [Read here](#)
- PEPAXTO (Melphalan Flufenamide) for injection. [Learn more here](#)
- Daratumumab, Carfilzomib, and Dexamethesone combination improves PFS in patients with relapse/refractory multiple myeloma. [Read more here](#)
- COVID-19 & Myeloma Patient Safety: [Click Here](#)

Educational Programs

- March 13: Patient & Family Webinar: The Latest COVID-19 Safety Variants. [Watch replay here](#)
- March 20: M-Power Charlotte Community Workshop From “Myeloma for Patients Who Are Just Getting Started” to the latest in treatments and research, this comprehensive program also features a myeloma patient’s story. [Watch replay here](#)
- March 20: Myeloma Treatment Discussion Tool. [Watch replay here](#)
- March 27: San Diego Area Regional Community Workshop: [Watch replay here](#)

Virtual Support Group Meeting Topics and Speakers

- Please contact Robin Tuohy for details on a variety of educational presentations to choose from for your upcoming virtual support group meetings. rtuohy@myeloma.org

[Facebook: /Myeloma](#) | [Twitter @IMFMyeloma](#) | [Instagram @IMFmyeloma](#)



Improving Lives **Finding the Cure**
 International Myeloma Foundation
 12650 Riverside Drive, Suite 206
 North Hollywood, California 91607
[Myeloma.org](#)